Clinical Trials Browser

INDUSTRY × selurampanel × Endocrine × Clear all

NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Phase 2 Completed

59 enrolled 6 charts

EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma